Trial Profile
A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2017
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary)
- Indications Carotid stenosis; Essential hypertension
- Focus Therapeutic Use
- Acronyms ALIVE
- Sponsors Takeda
- 20 May 2016 Status changed from recruiting to discontinued.
- 29 Feb 2016 Planned End Date changed from 1 Nov 2016 to 1 Jul 2017, according to ClinicalTrials.gov record.
- 29 Feb 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Jul 2017, according to ClinicalTrials.gov record.